You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Syngene, 3DC sign 5-year strategic collaboration

Capital Market 

Syngene International and Deerfield have signed an agreement to collaborate to advance therapeutic discovery projects, from target validation through to pharmacological proof of concept and preclinical evaluation.

This five-year collaboration unites the core skills of the investment management company Deerfield, through its drug discovery and development arm 3DC, and Syngene's integrated drug discovery (IDD) services. Deerfield Discovery and Development Corporation (3DC) is the drug discovery and development subsidiary of Deerfield Management Company (Deerfield).

3DC has selected Syngene as a key execution partner for a developing portfolio of molecular entities, spanning multiple therapeutic areas and modalities. The ultimate goal is to deliver much needed benefit to patients suffering from serious, unmet medical needs through innovation, scale, quality, and speed-to-market. The collaboration will start with immediate effect and is expected to run for an initial cycle of 5 years.

The announcement was made after market hours yesterday, 19 November 2020. Shares of Syngene International fell 0.98% to settle at Rs 567.40 yesterday.

Syngene International is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, November 20 2020. 08:33 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU